Key takeaways
- GHK-Cu is one molecule, the copper(II) complex of glycyl-L-histidyl-L-lysine; KLOW is a seller name for one vial that lists GHK-Cu, BPC-157, TB-500 and KPV.
- We found no published study, in any species, and no registered trial that gave the four together, and none comparing the mix with GHK-Cu alone (PubMed and ClinicalTrials.gov, 21 Nov 2026).
- GHK-Cu’s own record, in the studies cited here, is cell and animal work plus small human skin studies; none of it transfers to a mixed vial.
- Regulators set status one compound at a time, and none of the status documents we read names the mix.
- A lab report for a GHK-Cu vial has one identity to confirm; a report for a vial that lists four peptides has four.
01GHK-Cu and KLOW side by side
The same questions, asked of one compound and of a name for a mixed vial. Dated 21 November 2026.
| Question | GHK-Cu | KLOW |
|---|---|---|
| What the name refers to | One molecule: the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine | A seller name for one vial that mixes four peptides |
| Listed components | GHK-Cu | GHK-Cu, BPC-157, TB-500, KPV |
| Studied under that name | Yes: cell, animal and small human skin studies | No study found, in any species |
| Compared with the other | No study found | No study found |
| Evidence tier of the studies cited here | One small randomised skin study in people (T1), plus animal (T3) and cell (T4) studies | GHK-Cu as on the left. BPC-157: small human studies (T2) and animal studies (T3). TB-500: animal and cell studies (T3, T4). KPV: a mouse and cell study (T3, T4) |
| United States | Drugs@FDA lists no medicine containing it. FDA’s list of substances nominated for compounding (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, bulk drug substances under evaluation. It is not in HHS’s October 2026 draft policy | GHK-Cu as on the left. Drugs@FDA lists no medicine containing BPC-157, TB-500 or KPV. HHS’s October 2026 draft policy, which “is not binding”, names those three and covers single-ingredient products only |
| Australia | The TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” GHK-Cu has no entry by name in the Poisons Standard October 2026, which has group entries for copper compounds; we draw no scheduling conclusion of our own. | GHK-Cu as on the left. BPC-157 and TB-500 are in Schedule 4 and Appendix D. For KPV, the TGA statement on the left; we found no entry by name for KPV and draw no scheduling conclusion of our own. |
| United Kingdom | The emc database returned no results for GHK, copper tripeptide or prezatide (21 Nov 2026); it is not the full UK register | The same for BPC-157, TB-500 and KPV |
| Sport (WADA 2026 and 2027 Lists) | Not named. WADA says a peptide not specifically named “may still be prohibited” | GHK-Cu and KPV as on the left. BPC-157 (class S0) and TB-500 (class S2.3) are named, prohibited at all times |
| Identities a lab report has to confirm | One | Four |
If you searched “ghk cu vs klow”, the comparison is between one compound and a mixed vial that lists it: what is known about GHK-Cu is not known about the mix. What the name KLOW covers, component by component, and where each component stands: what is the “KLOW peptide”?
02What is the difference between GHK-Cu and KLOW?
One molecule on one side, four listed names on the other. The drawings show which molecules are listed, not how much of each.
GHK-Cu: one molecule
Glycyl-L-histidyl-L-lysine, a peptide of three amino acids, holding a copper(II) ion. The earliest papers we found on GHK in PubMed date from 1973.
KLOW: four listed names
GHK-Cu with BPC-157, TB-500 and KPV in one vial. No regulator or peer-reviewed source defines the mix or says how much of each it holds.
One identity, or four
A report for a GHK-Cu vial has one peptide to identify and measure. A report for a vial listing four has to identify and measure each one.
One purity percentage for a vial that lists four peptides cannot show that each one is present, or how much of each there is. Evidence attaches to what was studied, never to a name for a mix: peptide blends: one vial, no shared evidence.
03What has GHK-Cu been studied in, and does any of it cover the mix?
GHK-Cu’s own record, design and measures only. None of these studies gave GHK-Cu with another peptide.
| Study | Model and n | What was measured | Tier |
|---|---|---|---|
| Miller et al., 2006 | People: a randomised comparison of skin-care regimens with or without GHK-Cu after laser resurfacing around the mouth; 13 completed | Redness, by software and blinded evaluators; wrinkles and skin quality at 12 weeks; a patient questionnaire | T1, small |
| Maquart et al., 1993 | Rats with implanted wound chambers; n not given in the abstract | Dry weight, protein, collagen and DNA content of the chamber tissue | T3 |
| Maquart et al., 1988 | Fibroblasts in culture | Collagen production by the cells | T4 |
The 2006 trial is the one randomised study in people that we cite here; it is small, and it measured skin after a laser procedure. An animal or cell result is not evidence of an effect in people, and material sold online is not the product these studies tested. GHK-Cu’s guide grades its human evidence “Early human”: the GHK-Cu guide.
What GHK-Cu’s record says about the mix. Nothing. On 21 November 2026 we searched PubMed with the component names, quoted and unquoted: no paper names all four. Eight papers name GHK-Cu together with BPC-157, and each is a review, commentary or letter; the one that names KPV beside GHK-Cu is a review. No PubMed record uses KLOW as the name of a peptide mix, and ClinicalTrials.gov lists no trial that gives two or more of the four together.
04Where do GHK-Cu and the other three components stand with regulators and in sport?
Component by component. None of the status documents we read names the mix.
- Sep 2023FDA Category 2
BPC-157, TB-500 and KPV enter FDA’s list of compounding substances that may present significant safety risks.
- 22 Apr 2026Out of Category 2
HHS records that neither the placement nor the removal changed the status of the three under section 503A.
- 14 May 2026GHK-Cu under evaluation
FDA’s updated list places GHK-Cu, for certain routes of administration only, in Category 1. FDA says it intends to consult its compounding advisory committee before the end of February 2027.
- 23–24 Jul 2026Advisory committee meets
FDA staff propose not adding BPC-157, TB-500 or KPV to the 503A bulks list. HHS records that the committee voted in favour of each. GHK-Cu was not on the agenda.
- 1 Oct 2026Poisons Standard October 2026 in force
Australia’s current standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D. We found no entry by name for GHK-Cu or KPV.
- 30 Oct 2026HHS draft policy published
It names six peptides, including BPC-157, TB-500 and KPV, not GHK-Cu, and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice calls it a draft that “is not binding”.
- 1 Jan 2027WADA 2027 List takes effect
BPC-157 (class S0) and TB-500 (class S2.3) remain named. GHK-Cu and KPV are not named, and WADA says a peptide not specifically named “may still be prohibited”.
In the UK, the emc database of licensed-medicine information returned no results for any of the four names on 21 November 2026; it is not the full UK register. GHK-Cu’s US record, with its dates: is GHK-Cu legal in the US? Each KLOW component, country by country: the KLOW page. Sport: peptides and anti-doping.
05What we don’t know, and how to check a vial
There is no evidence to rank the single compound against the mix. These are the open questions, and the one check anyone can run.
We found no study that gave GHK-Cu together with BPC-157, TB-500 or KPV, in any species (PubMed and ClinicalTrials.gov, 21 Nov 2026).
Whether they stay stable in one vial, or change one another, is a separate question. We found no published data.
That needs the same model and measures, with a group for GHK-Cu alone and a group for the mix. We found none, published or registered.
Only that lot’s lab report can show it: one identity for a GHK-Cu vial, four identities and four amounts for a vial that lists four peptides.
How to read those lines on a report: how to read a COA.
This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.